Bariatric Surgery Reverses Subclinical Heart Disease
By HospiMedica International staff writers Posted on 18 Dec 2019 |
A new study suggests that weight loss surgery can benefit subclinical myocardial function in the severely obese, both with and without type 2 diabetes (T2D).
Researchers at the Quebec Heart and Lung Institute (Canada) conducted a study that included 38 obese patients who underwent bariatric surgery and 19 patients, matched for age and sex, who remained on the surgical waiting list. Pre-surgical measurements included echocardiography, body weight, blood pressure, blood lipids, and blood glucose. Six months into the study, patients in the surgery group had lost 26% of their total body weight, while those on the waiting list remained the same weight.
The results revealed that rates of comorbidities were significantly lower in the surgery group compared to the waiting list group: 30% versus 61% for hypertension, 5% versus 42% for dyslipidaemia, and 13% versus 40% for T2D, respectively. Of the patients in the surgery group with subclinical heart disease at the start of the study, 82% were normalized at six months after surgery. In contrast, subclinical cardiac disease worsened in 53% of patients on the waiting list during the same period. The study was presented at the annual EuroEcho scientific congress, held during December 2019 in Vienna (Austria).
“Bariatric surgery was conceived for weight loss; our study indicates it may also reverse subclinical heart dysfunction; its reversal could translate into improved prognosis,” said lead author and study presenter Marie-Eve Piché, MD. “Interestingly, remission of T2D after bariatric surgery was associated with improvement in subclinical heart function. Conversely, obese individuals with T2D who remained on the surgical waiting list showed a worsening in their subclinical myocardial function during follow-up.”
For patients with morbid obesity, bariatric surgery, including Roux-en-Y gastric bypass (RYGB) surgery, is an effective treatment for weight loss and diseases associated with obesity. However, various medical, nutritional, and surgical symptoms requiring treatment may occur after RYGB surgery and may impair patients' quality of life.
Related Links:
Quebec Heart and Lung Institute
Researchers at the Quebec Heart and Lung Institute (Canada) conducted a study that included 38 obese patients who underwent bariatric surgery and 19 patients, matched for age and sex, who remained on the surgical waiting list. Pre-surgical measurements included echocardiography, body weight, blood pressure, blood lipids, and blood glucose. Six months into the study, patients in the surgery group had lost 26% of their total body weight, while those on the waiting list remained the same weight.
The results revealed that rates of comorbidities were significantly lower in the surgery group compared to the waiting list group: 30% versus 61% for hypertension, 5% versus 42% for dyslipidaemia, and 13% versus 40% for T2D, respectively. Of the patients in the surgery group with subclinical heart disease at the start of the study, 82% were normalized at six months after surgery. In contrast, subclinical cardiac disease worsened in 53% of patients on the waiting list during the same period. The study was presented at the annual EuroEcho scientific congress, held during December 2019 in Vienna (Austria).
“Bariatric surgery was conceived for weight loss; our study indicates it may also reverse subclinical heart dysfunction; its reversal could translate into improved prognosis,” said lead author and study presenter Marie-Eve Piché, MD. “Interestingly, remission of T2D after bariatric surgery was associated with improvement in subclinical heart function. Conversely, obese individuals with T2D who remained on the surgical waiting list showed a worsening in their subclinical myocardial function during follow-up.”
For patients with morbid obesity, bariatric surgery, including Roux-en-Y gastric bypass (RYGB) surgery, is an effective treatment for weight loss and diseases associated with obesity. However, various medical, nutritional, and surgical symptoms requiring treatment may occur after RYGB surgery and may impair patients' quality of life.
Related Links:
Quebec Heart and Lung Institute
Latest Surgical Techniques News
- Caterpillar Robot with Built-In Steering System Crawls Easily Through Loops and Bends
- Tiny Wraparound Electronic Implants to Revolutionize Treatment of Spinal Cord Injuries
- Small, Implantable Cardiac Pump to Help Children Awaiting Heart Transplant
- Gastrointestinal Imaging Capsule a Game-Changer in Esophagus Surveillance and Treatment
- World’s Smallest Laser Probe for Brain Procedures Facilitates Ablation of Full Range of Targets
- Artificial Intelligence Broadens Diagnostic Abilities of Conventional Coronary Angiography
- AI-Powered Surgical Visualization Tool Supports Surgeons' Visual Recognition in Real Time
- Cutting-Edge Robotic Bronchial Endoscopic System Provides Prompt Intervention during Emergencies
- Handheld Device for Fluorescence-Guided Surgery a Game Changer for Removal of High-Grade Glioma Brain Tumors
- Porous Gel Sponge Facilitates Rapid Hemostasis and Wound Healing
- Novel Rigid Endoscope System Enables Deep Tissue Imaging During Surgery
- Robotic Nerve ‘Cuffs’ Could Treat Various Neurological Conditions
- Flexible Microdisplay Visualizes Brain Activity in Real-Time To Guide Neurosurgeons
- Next-Gen Computer Assisted Vacuum Thrombectomy Technology Rapidly Removes Blood Clots
- Hydrogel-Based Miniaturized Electric Generators to Power Biomedical Devices
- Custom 3D-Printed Orthopedic Implants Transform Joint Replacement Surgery